Short-acting GLP-1 receptor agonists include exenatide (Byetta, with limited US availability) and lixisenatide (Adlyxin, discontinued in the US market)
"Everybody is debating, 'Does B12 really make a clinical difference?'" says Brunner
NICE has approved semaglutide 2.4 mg (Wegovy) for use within specialist weight management services (NICE TA875), subject to specific eligibility criteria including a BMI of 35 kg/m or above (or 32.5 kg/m or above in people from certain ethnic minority backgrounds at higher metabolic risk) alongside at least one weight-related comorbidity
Standard BAC water can work, but it is often more uncomfortable
Stick to bland, easily digestible options during the first week of a new dose
Here's all you need to know To view or add a comment, sign in 1,463,826 followers